Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sidekick cell adhesion molecule 2 (SDK2) is a single-pass transmembrane protein of the immunoglobulin superfamily, consisting of a signal sequence, six immunoglobulin-like (Ig) domains, thirteen fibronectin type III (FNIII) domains, a transmembrane region, and a short cytoplasmic tail terminated by a PDZ-binding motif[1][2][3]. SDK2 mediates homophilic cell-cell adhesion critical for the formation of specific synaptic connections in the vertebrate retina by ensuring that neurons innervate correct target layers, thereby contributing to visual circuit assembly. SDK2 does not act as a classical “receptor” for small molecules or drugs; instead, its function is to guide and stabilize cell-cell contacts primarily during neural development[1][3]. No approved therapeutic drugs, clinical trials, or direct disease associations have been documented for SDK2, though it may be relevant in developmental neurobiology and potentially in future studies of disorders with synaptic miswiring[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sidekick cell adhesion molecule 2 (SDK2).